Zimbabwe has turned down a significant American health deal worth 367 million US dollars (272 million pounds) over five years due to the United States' demand for confidential biological samples.
This move came to light after a government memo dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesman has since stated that the United States was requesting genetic material for scientific study and commercial gain but refused to guarantee the resulting advantages from future treatments.
"We are forced to start the difficult and regrettable process of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged continued negotiations to reach a agreement acceptable to both sides so the country's vital HIV programme can proceed.
Wider Context
This rejection comes after a comparable case in neighbouring Kenya, where a high court halted a related deal with the US after concerns were filed about the safety of citizens' health data.
After resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump argued its spending was "inefficient" and his government was seeking government-to-government agreements to boost openness and accountability.
Based on reports, 16 African countries have to date signed these new agreements, representing over $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership might have yielded extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy via American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, without any corresponding assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"Put simply, our nation would supply the basic resources for medical research without any assurance that the resulting innovations would be available to our people if a future disease outbreak arise."
Sovereignty and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral deals were undermining systems already set up through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to deal with potential pandemics.
"This system is designed to guarantee that when a country provides its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
These objections over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome continued discussions with our American counterparts on how future co-operation could be arranged in a manner that honours the sovereignty and dignity of each country."
Health Experts Response
Medical experts stated it understood the official position, but suggested that negotiations should continue since much of the country's HIV programmes were funded by international support.
"In cases where specific concerns exist, including those relating to information security or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," it commented.
The halted deal highlights the ongoing challenges between accepting vital foreign assistance and protecting local interests in an increasingly data-driven world.